Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.
Phase 4
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Registration Number
- NCT00184626
- Lead Sponsor
- Novo Nordisk A/S
- Brief Summary
This trial is conducted in Asia. The aim of the trial is to compare the glycaemic control of Insulin glargine versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in combination with metformin in subjects with Type 2 Diabetes.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 97
Inclusion Criteria
- Type 2 diabetes
- Body mass index equal to or lesser than 35.0 kg/m2
- Currently treated with oral hypoglycaemic drug
Exclusion Criteria
- Known hypoglycaemia unawareness or recurrent major hypoglycaemia as judged by the Investigator
- Any condition that the Investigator and/or the Sponsor feel would interfere with trial participation or evaluation of results
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method HbA1c Measured at end of treatment (26 weeks)
- Secondary Outcome Measures
Name Time Method safety variables other glycemic variables Fasting plasma glucose value
Trial Locations
- Locations (1)
Novo Nordisk Investigational Site
🇹🇷Istanbul, Turkey